Replies to post #300123 on NorthWest Biotherapeutics Inc (NWBO)

[Sojourner55]

However the citations she listed (7,14) about potential patient selection bias does not say anything about patient selection bias unless I'm missing something or she just pulled 2 citations hoping no one would fact check it.

While the interim analysis from the trial showed an eight-month OS survival benefit for the addition of DCVax-L to SoC, key stakeholders in the field have indicated potential patient selection bias (7,14).

7. The microenvironmental landscape of brain tumors
Daniela F. Quail1 and Johanna A. Joyce2,3,*

DC vaccines are likewise gaining significant clinical attention as an alternative strategy to stimulate T cell responses (Anguille et al., 2014; Palucka and Banchereau, 2012). DCVax-L, an autologous tumor lysate-pulsed DC vaccine, is furthest along in this regard, with early clinical trials reporting a median survival of 31.4 months in glioblastoma patients (Prins et al., 2011) – an improvement over historical controls of 14.6 months for the standard of care comprising radiation and temozolomide chemotherapy (Stupp et al., 2005). As a result, Phase III trials have now been initiated (ClinicalTrials.gov identifier: NCT00045968) (Table 1).

And

14 is a press release from Celldex and I don't see anything about patient selection bias.

14. https://ir.celldex.com/news-releases/news-release-details/data-safety-and-monitoring-board-recommends-celldexs-phase-3

[biosectinvestor]

There was a doctor a few years ago who had run a competing vaccine trial I believe, who alleged this and Dr. Liau put a nail in it. It’s not true, in fact the population is not favorable at all, but there was no selection bias. That guy just pulled junk from his but hole.

Now this author has stumbled on the old comment and revived it by not actually looking further. Typical crap to happen just before news. This is the stuff that happens all the time, and you’re never sure how it took back to live in zombie form.

There are going to be a lot of zombie ideas.

[alexander77]

Even the competition has no arguments why dvcax-l would fail. This is going to explode! TLD in September!!

[biosectinvestor]

Her keyword there is “potential” bias. I think she likely already knows it was discredited IMHO or did not bother to review the further discussions, and just threw that in there for her own protection given that there has been criticism. That’s behind covering language. She’s just noting criticism.

People know there are critics so they probably nod to them regardless of the credibility of the critique. It’s not uncommon for non-expert journalists.

By the way, this is to my best recollection, I will let one of the other resident posters who drilled down at the time confirm it. My memory is what it is... but I don’t have all the details.